Drugs / EBOPIPRANT
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT03369262 | Jan 2018 → Jul 2020 | — | ObsEva SA | Unknown | No outcome recorded |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2021-07-27 | Organon and Co | Organon and ObsEva Enter Global License Agreement to Develop and Commercialize Ebopiprant (OBE022), an Investigational Agent Being Evaluated as a First-in-Class Treatment for Preterm Labor organon.com ↗ |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | EBOPIPRANT | ChEMBL registry synonym — accepted as the source's own label CHEMBL3975522 ↗ |
| Known as | OBE022 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03369262 ↗ |
| Modality | Small molecule | — CHEMBL3975522 ↗ |
| Route | Oral | “OBE022 will be given orally from Day 1 to Day 7.” NCT03369262 ↗ |